Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 105

1.

Antipsychotic-induced metabolic and cardiovascular side effects in schizophrenia: a novel mechanistic hypothesis.

Scigliano G, Ronchetti G.

CNS Drugs. 2013 Apr;27(4):249-57. doi: 10.1007/s40263-013-0054-1.

PMID:
23533011
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

[Drawing up guidelines for the attendance of physical health of patients with severe mental illness].

Saravane D, Feve B, Frances Y, Corruble E, Lancon C, Chanson P, Maison P, Terra JL, Azorin JM; avec le soutien institutionnel du laboratoire Lilly.

Encephale. 2009 Sep;35(4):330-9. doi: 10.1016/j.encep.2008.10.014. Epub 2009 Jul 9. French.

PMID:
19748369
[PubMed - indexed for MEDLINE]
3.

[Schizophrenia, diabetes mellitus and antipsychotics].

Gury C.

Encephale. 2004 Jul-Aug;30(4):382-91. Review. French.

PMID:
15538314
[PubMed - indexed for MEDLINE]
4.

[Brazilian Consensus on second-generation antipsychotics and metabolic disorders].

Elkis H, Gama C, Suplicy H, Tambascia M, Bressan R, Lyra R, Cavalcante S, Minicucci W.

Rev Bras Psiquiatr. 2008 Mar;30(1):77-85. Portuguese.

PMID:
18373022
[PubMed - indexed for MEDLINE]
Free Article
5.

[Metabolic side effects of risperidone in early onset schizophrenia].

Goeb JL, Marco S, Duhamel A, Kechid G, Bordet R, Thomas P, Delion P, Jardri R.

Encephale. 2010 Jun;36(3):242-52. doi: 10.1016/j.encep.2009.10.008. Epub 2009 Dec 1. French.

PMID:
20620267
[PubMed - indexed for MEDLINE]
6.

Cardiovascular side-effects of antipsychotic drugs: the role of the autonomic nervous system.

Leung JY, Barr AM, Procyshyn RM, Honer WG, Pang CC.

Pharmacol Ther. 2012 Aug;135(2):113-22. doi: 10.1016/j.pharmthera.2012.04.003. Epub 2012 Apr 27. Review.

PMID:
22565090
[PubMed - indexed for MEDLINE]
7.

Cardiovascular risks of atypical antipsychotic drug treatment.

Drici MD, Priori S.

Pharmacoepidemiol Drug Saf. 2007 Aug;16(8):882-90. Review.

PMID:
17563919
[PubMed - indexed for MEDLINE]
8.

World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia.

Tandon R, Belmaker RH, Gattaz WF, Lopez-Ibor JJ Jr, Okasha A, Singh B, Stein DJ, Olie JP, Fleischhacker WW, Moeller HJ; Section of Pharmacopsychiatry, World Psychiatric Association.

Schizophr Res. 2008 Mar;100(1-3):20-38. doi: 10.1016/j.schres.2007.11.033. Epub 2008 Feb 19. Review.

PMID:
18243663
[PubMed - indexed for MEDLINE]
9.

Differential metabolic effects of antipsychotic treatments.

Haupt DW.

Eur Neuropsychopharmacol. 2006 Sep;16 Suppl 3:S149-55. Epub 2006 Jul 25. Review.

PMID:
16872808
[PubMed - indexed for MEDLINE]
10.

Non-neurological and metabolic side effects in the Cost Utility of the Latest Antipsychotics in Schizophrenia Randomised Controlled Trial (CUtLASS-1).

Peluso MJ, Lewis SW, Barnes TR, Jones PB.

Schizophr Res. 2013 Mar;144(1-3):80-6. doi: 10.1016/j.schres.2012.12.008. Epub 2013 Jan 11.

PMID:
23313462
[PubMed - indexed for MEDLINE]
11.

Management of schizophrenia with obesity, metabolic, and endocrinological disorders.

Monteleone P, Martiadis V, Maj M.

Psychiatr Clin North Am. 2009 Dec;32(4):775-94. doi: 10.1016/j.psc.2009.08.003. Review.

PMID:
19944883
[PubMed - indexed for MEDLINE]
12.

Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.

Citrome L, Holt RI, Walker DJ, Hoffmann VP.

Clin Drug Investig. 2011;31(7):455-82. doi: 10.2165/11589060-000000000-00000. Review.

PMID:
21495734
[PubMed - indexed for MEDLINE]
13.

[Atypical antipsychotics and sexual dysfunction: five case-reports associated with risperidone].

Haefliger T, Bonsack C.

Encephale. 2006 Jan-Feb;32(1 Pt 1):97-105. French.

PMID:
16633296
[PubMed - indexed for MEDLINE]
14.

Evolution of schizophrenia drugs: a focus on dopaminergic systems.

Nikam SS, Awasthi AK.

Curr Opin Investig Drugs. 2008 Jan;9(1):37-46. Review.

PMID:
18183530
[PubMed - indexed for MEDLINE]
15.

Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.

Newcomer JW.

CNS Drugs. 2005;19 Suppl 1:1-93. Review.

PMID:
15998156
[PubMed - indexed for MEDLINE]
16.

[Schizophrenia and antipsychotics associated with the metabolic syndrome. An overview].

Scheepers-Hoeks AM, Wessels-Basten SJ, Scherders MJ, Bravenboer B, Loonen AJ, Kleppe RT, Grouls RJ.

Tijdschr Psychiatr. 2008;50(10):645-54. Review. Dutch.

PMID:
18951343
[PubMed - indexed for MEDLINE]
Free Article
17.

Current use of atypical antipsychotics.

Müller-Spahn F.

Eur Psychiatry. 2002 Aug;17 Suppl 4:377s-384s. Review.

PMID:
23573608
[PubMed - indexed for MEDLINE]
18.

Safety considerations of the use of second generation antipsychotics in the treatment of major depression: extrapyramidal and metabolic side effects.

DeBattista C, DeBattista K.

Curr Drug Saf. 2010 Jul 2;5(3):263-6. Review.

PMID:
20394571
[PubMed - indexed for MEDLINE]
19.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
[PubMed - indexed for MEDLINE]
20.

Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.

De Hert M, Yu W, Detraux J, Sweers K, van Winkel R, Correll CU.

CNS Drugs. 2012 Sep 1;26(9):733-59. doi: 10.2165/11634500-000000000-00000. Review.

PMID:
22900950
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk